LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,047 | -16.3% | 23,769 | 0.0% | 0.00% | – |
| Q2 2023 | $33,514 | +5.5% | 23,769 | +12.3% | 0.00% | – |
| Q1 2023 | $31,760 | +34.6% | 21,173 | +5.0% | 0.00% | – |
| Q4 2022 | $23,602 | -1.7% | 20,173 | -4.5% | 0.00% | – |
| Q3 2022 | $24,000 | -22.6% | 21,115 | +7.7% | 0.00% | – |
| Q2 2022 | $31,000 | +3.3% | 19,613 | 0.0% | 0.00% | – |
| Q1 2022 | $30,000 | -26.8% | 19,613 | +16.7% | 0.00% | – |
| Q4 2021 | $41,000 | -2.4% | 16,813 | 0.0% | 0.00% | – |
| Q3 2021 | $42,000 | -12.5% | 16,813 | 0.0% | 0.00% | – |
| Q2 2021 | $48,000 | +20.0% | 16,813 | -0.3% | 0.00% | – |
| Q1 2021 | $40,000 | +14.3% | 16,857 | -15.2% | 0.00% | – |
| Q4 2020 | $35,000 | +218.2% | 19,878 | +76.3% | 0.00% | – |
| Q3 2020 | $11,000 | +10.0% | 11,278 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | +11.1% | 11,278 | 0.0% | 0.00% | – |
| Q1 2020 | $9,000 | -18.2% | 11,278 | -8.1% | 0.00% | – |
| Q4 2019 | $11,000 | -8.3% | 12,278 | +0.5% | 0.00% | – |
| Q3 2019 | $12,000 | – | 12,213 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |